Lobeglitazone/Sitagliptin

洛贝格列酮/西格列汀

Report date: 2024/11/21 20:00:04

Base Information

Drug NameLobeglitazone/Sitagliptin
Drug Alias NameLobeglitazone+Sitagliptin西格列汀+洛贝格列酮Sitagliptin+Lobeglitazone西格列汀/洛贝格列酮Sitagliptin/Lobeglitazone +[7] 
ClassificationSmall molecules
Mechanisms of ActionPeroxisome proliferator-activated receptor γ agonistsDipeptidyl peptidase IV inhibitorsPeroxisome proliferator-activated receptor α agonists
TargetsDipeptidyl peptidase IVPeroxisome proliferator-activated receptor γPeroxisome proliferator-activated receptor α
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsYes Sitagliptin Phosphate MonohydrateLobeglitazone Sulfate
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesChong Kun Dang Pharmaceutical Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesChong Kun Dang Pharmaceutical Corp
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A